Levofloxacina Optacare Ntc (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition halts bacterial cell division and leads to rapid bacterial cell death, providing a bactericidal effect against a broad range of ocular pathogens.

The dosing regimen for Levofloxacina Optacare Ntc is determined by the prescribing clinician based on the severity of the infection, patient age, and clinical response. The prescriber will specify the number of drops, frequency, and duration of therapy.

Safety data for levofloxacin use during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levofloxacina Optacare Ntc belongs to the fluoroquinolone class, offering broad‑spectrum coverage and excellent ocular penetration. Compared with older agents such as ciprofloxacin, levofloxacin often requires less frequent dosing and may retain activity against some resistant strains, though choice of therapy should be guided by local susceptibility patterns.

Store the ophthalmic solution at room temperature below 25 °C, in the original packaging, protected from moisture and direct light. Keep the bottle tightly closed when not in use and discard any product that appears discolored or contaminated.

The medication is applied as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill the prescribed number of drops without touching the tip of the bottle to the eye or any surface. Close the eye gently after administration.

Serious adverse events, although rare, include severe allergic reactions (anaphylaxis), corneal ulceration or perforation, significant ocular pain, vision loss, and systemic hypersensitivity syndromes such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any excipients in the formulation should avoid this product. It is also contraindicated in patients with a history of severe ocular surface disease where fluoroquinolone use could exacerbate the condition.